Dr. Yasuhiro Oki, MD

Dr. Oki practices at Stanford Health Care Tri-Valley in Pleasanton, California, part of Stanford University.

Dr. Oki's NPI, 1265742274, was assigned on October 12, 2010. Dr. Oki graduated from Graduate School of Medicine and Faculty of Medicine, The University of Tokyo in 1998. Dr. Oki holds Texas license N6548.

Dr. Oki's primary practice is Stanford Health Care Tri-Valley, at 5555 West Las Positas Boulevard, Pleasanton, CA 94588 in Alameda County. The practice phone is (925) 847-3000.

Dr. Oki's primary practice is Stanford Health Care Tri-Valley in Pleasanton, California, part of Stanford University. The medical group on file is Stanford Medicine Partners.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Oki practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Oki's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Oki is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Oki's licenses on file in 2 states: Texas and California.

CMS data shows 65 Medicare services from Dr. Oki across 2 procedure codes in 2023, for 14 Medicare patients. Medicare paid $7,387 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 14 Medicare patients who saw Dr. Oki in 2024. The largest group is under 65, with 0 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 3.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Oki's median patient age at 65, with 0% women.

In 2017, Dr. Oki wrote 195 Medicare Part D claims. They cover 10 drugs, with $9,027 in total drug cost. In 2016, CMS named 89 claims across 4 drugs.

Dmand AI links 167 papers to Dr. Oki, published from 2003 to 2022. 2018 was the busiest year, with 21. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Doxorubicin and Hodgkin Disease. Dr. Oki has published most often in Leuk Lymphoma. Dr. Oki's most frequent co-authors are Luis E. Fayad, MD, Michelle A. Fanale, MD and Jason R. Westin, MD.

Dmand AI links Dr. Oki to 10 clinical trials, 5 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Lymphoma, Lymphoma, Large B-Cell, Diffuse and Hodgkin Disease. M.D. Anderson Cancer Center sponsors the most, 6.

CMS Open Payments shows 9 general payments to Dr. Oki from 4 drug and device companies from 2016 to 2019. Speaker and faculty fees make up the largest share, 69% of the total. Spectrum Pharmaceuticals Inc. paid the most, $4,540. It also lists 1 research payment totaling $1,050 in 2017.

Dr. Oki graduated from Graduate School of Medicine and Faculty of Medicine, The University of Tokyo in 1998.

Dr. Oki is in network with 3 carriers, including Elevance, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 3. Check the plan with the practice before a visit.